All In Biotech

Drug Trial Radar · NCT07811193

A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

A Phase 2, Randomized, Open-label Study of VVD-133214 in COmbination With Pembrolizumab Compared to Pembrolizumab Monotherapy in Participants With Advanced Colorectal Adenocarcinoma (CRC) Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (DMMR)

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Sep 11, 2026

Primary completion

Jun 30, 2028

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Vividion Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Bayer
First posted
Sep 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat people with advanced colorectal cancer. Colorectal cancer (cancer of the colon or rectum) is one of the most common cancers worldwide. Treatments include surgery, chemotherapy, radiotherapy, and immunotherapy; however, these treatments do not work for everyone, may cause serious adverse events or may stop working eventually. New treatments and treatment combinations are needed, especially for cancers that cannot be removed with surgery or that have spread to other parts of the body (called advanced or metastatic cancer). Cells normally repair themselves when mistakes happen as they divide. But in some people with cancer, the repair system does not work properly because of a problem called dMMR (deficient mismatch repair). As a result, mistakes build up in the cell's DNA, leading to a condition called MSI (microsatellite instability). Over time, these changes can cause cells to grow and behave abnormally, contributing to the development and growth of cancer. To survive, some cancer cells with dMMR or MSI rely on a protein called Werner helicase. This protein helps repair some of the DNA damage allowing them to keep growing. Because these cancer cells depend more on Werner helicase than healthy cells, blocking this protein may help stop cancer cells from surviving while having less effect on healthy cells. The study drug, VVD-133214, is designed to block the Werner helicase protein. Blocking this protein may help stop cancer cells from growing, while causing less harm to healthy cells. VVD-133214 is being studied in combination with pembrolizumab, an approved immunotherapy that helps the immune system recognize and attack cancer cells. This study will test the combination of VVD-133214 and pembrolizumab in people with advanced colorectal cancer with MSI and/or dMMR who have not yet received treatment for their advanced disease. The study aims to find the best dose of VVD-133214 in combination with pembrolizumab and to test whether the combination is more effective than pembrolizumab alone. Participants will receive treatment with VVD-133214 for as long as it can help them and does not cause serious adverse events. Treatment with pembrolizumab will stop after two years. Participants can also stop treatment at any time. During the study, participants will have regular visits with the study doctor for tests, scans, and check-ups. These visits help check how well the cancer is responding to the treatment and monitor the participants' health. The study will also monitor adverse events, which are any new or worsening medical problems that can happen during the study. Doctors record all adverse events, irrespective of whether the study doctor believes they are related to the study treatments, to help ensure participants' safety throughout the study. After stopping treatment, participants will return for follow-up visits: 30 days after their last dose of VVD-133214 and/or 100 days after their last dose of pembrolizumab. After that, participants will have long-term follow-up visits every 90 days for as long as they agree to continue participating in follow-up.

Conditions

  • Colorectal Adenocarcinoma

Interventions

  • VVD-133214Drug

    VVD-133214 will be administered orally

  • PembrolizumabDrug

    Pembrolizumab will be administered by intravenous infusion (IV) every three weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Landmark progression-free survival (PFS) rate at 6 months, as assessed by the investigatorTime frame: From start of study treatment until end of follow-up (up to approximately 36 months)

Locations

123 sites in 22 countries. Site status is shown where the registry gives one.

  • University of Arizona Cancer Center - North Campus

    Tucson, Arizona · Not yet recruiting

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Not yet recruiting

  • Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit

    Detroit, Michigan · Not yet recruiting

  • Mary Babb Randolph Cancer Center

    Morgantown, West Virginia · Not yet recruiting

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Centro Medico Fleischer

    Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Instituto Alexander Fleming

    Buenos Aires, Buenos Aires, Argentina · Not yet recruiting

  • Investigaciones Oncológicas C Colón

    Mar del Plata, Buenos Aires, Argentina · Not yet recruiting

  • Sanatorio Allende | Departamento de Investigación Clínica

    Córdoba, Córdoba Province, Argentina · Not yet recruiting

  • Fundación Intecnus

    Bariloche, Río Negro Province, Argentina · Not yet recruiting

  • Sanatorio Parque - Oncology

    Rosario, Santa Fe Province, Argentina · Not yet recruiting

  • Institut Jules Bordet - Clinique D'Oncology

    Brussels, Brussels Capital, Belgium · Not yet recruiting

  • UZ Leuven - Digestive oncology

    Leuven, Flemish Brabant, Belgium · Not yet recruiting

  • CHU Helora - Hopital de La Louvière - Site Jolimont - Oncology department

    La Louvière, Hainaut, Belgium · Not yet recruiting

  • UZ Gent - Digestive Oncology

    Ghent, Oost-Vlaaanderen, Belgium · Not yet recruiting

  • AZ Delta - Digestive oncology

    Roeselare, West-Vlaanderen, Belgium · Not yet recruiting

  • Hospital Evangélico de Cachoeiro de Itapemirim

    Vitória, Espírito Santo, Brazil · Not yet recruiting

  • Hospital Araujo Jorge Associaçao de Combate ao Cancer em Goias

    Goiânia, Goiás, Brazil · Not yet recruiting

  • Nucleo de Ensino e Pesquisa do Hospital de Clinicas de Ijuí

    Ijuí, Rio Grande do Sul, Brazil · Not yet recruiting

  • Unidade de Pesquisas Clinicas em Oncologia

    Pelotas, Rio Grande do Sul, Brazil · Not yet recruiting

  • NAIC - Instituto do Cancer

    Bauru, São Paulo, Brazil · Not yet recruiting

  • Fundacao Pio XII - Hospital de Cancer de Barretos

    Jaú, São Paulo, Brazil · Not yet recruiting

  • Instituto do Cancer do Estado de Sao Paulo

    São Paulo, São Paulo, Brazil · Not yet recruiting

  • Hospital Sirio Libanes - Oncology_Sao Paulo

    São Paulo, São Paulo, Brazil · Not yet recruiting

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China · Not yet recruiting

  • Beijing Cancer Hospital - Oncology Department

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • The Sixth Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Shandong University - Shandong Cancer Hospital

    Jinan, Shandong, China · Not yet recruiting

  • Zhongshan Hospital, Fudan University

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • West China Hospital Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China · Not yet recruiting

  • Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department

    Hangzhou, Zhejiang, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

  • CHRU de Besancon - Hopital Jean Minjoz - Medical Oncology

    Besançon, Bourgogne-Franche-Comté, France · Not yet recruiting

  • Unicancer Dijon - Centre Georges Francois Leclerc - Oncologie medicale

    Dijon, Bourgogne-Franche-Comté, France · Not yet recruiting

  • CHU Brest - Hopital La Cavale Blanche - service oncologie medicale

    Brest, Brittany Region, France · Not yet recruiting

  • Unicancer Marseille - Institut Paoli-Calmettes - Oncologie medicale

    Marseille, Provence-Alpes-Côte d'Azur Region, France · Not yet recruiting

Showing 40 of 123 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.